Supersize my Pipeline
| April 1, 2009
Will Exelixis's novel approach pay off in the current economic climate?
BioBusiness
Most Recent
Personalized Meddling
| March 1, 2009
Frankie Trull wants to sell your company to Congress.
Profiting from Pluripotency
| February 1, 2009
How companies plan to make money (really) off of embryonic stem cells.
The Mentorship Market
| January 1, 2009
New organizations want to help you succeed in biotech - for free.
Morale Mire
| December 1, 2008
FDA scientists are increasingly unhappy, due to in-house pressures and public criticism. How can the agency restore what it once was?
Serotonin, Repurposed
| November 1, 2008
Immune Control CEO Stephen Roth is banking on a controversial hypothesis and is fashioning ways to block a neurotransmitter to fight autoimmune disease.
The Orphan Drug Act Turns 25
| October 1, 2008
The legislation is credited with building biotech and spawning hundreds of drugs for rare diseases. So why do some analysts hesitate to call it a success?
Chasing Challenges
| September 1, 2008
AstraZeneca's Karen Gotting-Smith is using a newly-created position to tackle some old problems.
Success from Failure
| August 1, 2008
John Prakash was once denied a job because of the way he looked. Now he spends his career talking about why diversity is crucial to drug development.
Irreverent Genetics
| July 1, 2008
At Merck, Eric Schadt takes an iconoclastic approach to drug discovery - and dressing.
Follow The Scientist
Advertisement
Stay Connected with The Scientist
-
The Scientist Magazine
-
The Scientist Careers
-
Neuroscience Research Techniques
-
Genetic Research Techniques
-
Cell Culture Techniques
-
Microbiology and Immunology
-
Cancer Research and Technology
Current Issue
